The ATAC adjuvant breast-cancer trial: Six-year results of the endometrial subprotocol

Postmenopausal women with localised, early breast cancer (n = 285) were enrolled in a prospective subprotocol of the 'arimidex, tamoxifen, alone or in combination' (ATAC) trial to assess gynaecological abnormalities arising during treatment with anastrozole (1 mg/day) or tamoxifen (20 mg/d...

Full description

Saved in:
Bibliographic Details
Published in:Journal of obstetrics and gynaecology 2010-08, Vol.30 (6), p.596-604
Main Authors: Duffy, S., Jackson, T. L., Lansdown, M., Philips, K., Wells, M., Clack, G., Bianco, A. R.
Format: Article
Language:English
Subjects:
Adjuvant treatment
Adult
anastrozole
Antineoplastic Agents, Hormonal - administration & dosage
Breast cancer
Breast Neoplasms - drug therapy
Chemotherapy, Adjuvant
Drugs
endometrial abnormalities
Endometrium - drug effects
Endometrium - pathology
Estrogens
Female
Gynecology
Humans
Medical treatment
Menopause
Middle Aged
Nitriles - administration & dosage
Pharmacology
Postmenopause
tamoxifen
Tamoxifen - administration & dosage
Treatment Outcome
Triazoles - administration & dosage
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Postmenopausal women with localised, early breast cancer (n = 285) were enrolled in a prospective subprotocol of the 'arimidex, tamoxifen, alone or in combination' (ATAC) trial to assess gynaecological abnormalities arising during treatment with anastrozole (1 mg/day) or tamoxifen (20 mg/day). After 6 years' follow-up, there appeared to be non-significantly fewer endometrial abnormalities with anastrozole than with tamoxifen (12.4% vs 20.2%, odds ratio 0.52; 95% confidence intervals 0.20, 1.32; p = 0.17). The time to first endometrial abnormality was non-significantly longer for patients receiving anastrozole compared with tamoxifen (hazard ratio 0.57; 95% confidence intervals 0.26, 1.22; p = 0.15), with most abnormalities occurring within the first year of treatment. Fewer patients treated with anastrozole appeared to require medical intervention for endometrial abnormalities, compared with patients on tamoxifen. This study showed that there was no significant difference in endometrial pathology between anastrozole and tamoxifen treatment groups.
ISSN:0144-3615
1364-6893
DOI:10.3109/01443615.2010.492433